New Delhi, Dec. 2 -- Amid rising demand for weight-loss drugs, Eli Lilly announced on Monday that it was cutting the price of its popular obesity drug Zepbound for US patients, as it moves to make the medicine more accessible in line with the Trump administration's goals.

The price of single-dose vials of the weight loss drug Zepbound has been reduced on Eli Lilly's direct-to-consumer platform, LillyDirect, as the company also races to compete with its rival Novo Nordisk.

In a statement on Monday, Eli Lilly confirmed discounts of up to 20% on Zepbound.

Patients typically start at lower doses, before moving to higher strengths for more weight loss.

This is the second time the company has cut down the prices of Zepbound on LillyDirect....